[1] Afshari M, Janbabaei G, Bahrami MA, et al. Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer[J]. Plos One, 2017, 12(6):e0178527.
[2] Gee HE, Camps C, Buffa FM, et al. Hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer[J]. Cancer, 2010, 116(9): 2148-2158.
[3] Alan Ka-Lun Kai, Lo Kong Chan, Regina Cheuk-Lam Lo, et al. Down-regulation of timp2 by hif-1alpha/mir-210/hif-3alpha regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma[J]. Hepatology (Baltimore, Md), 2016, 64(2): 473-487.
[4] Chang Y, Yan W, He X, et al. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions[J]. Gastroenterology, 2012, 143(12): 177-187.
[5] Ho AS, Huang X, Cao HB, et al. Circulating mir-210 as a novel hypoxia marker in pancreatic cancer[J]. Translational Oncology, 2010, 3(2): 109-113.
[6] Xiaoming Yang, Lei Shi, Chengzhi Yi, et al. Mir-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1[J]. Am J Cancer Res, 2017, 7(8): 1738-1753.
[7] Yuchen Liu, Yonghua Han, Hu Zhang, et al. Synthetic mirna-mowers targeting mir-183-96-182 cluster or mir-210 inhibit growth and migration and induce apoptosis in bladder cancer cells[J]. PloS One, 2012, 7(12): e52280.
[8] Ren D, Yang Q, Dai Y, et al. Oncogenic mir-210-3p promotes prostate cancer cell emt and bone metastasis via nf-kappab signaling pathway[J]. Mol Cancer, 2017, 16(1): 117.
[9] Lan H, Lu H, Wang X, et al. MicroRNAs as potential biomarkers in cancer: opportunities and challenges[J]. Bio Med Res Int, 2015, 2015(1): 125094.
[10]Li P, Xue WJ, Feng Y, et al. Microrna-205 functions as a tumor suppressor in colorectal cancer by targeting camp responsive element binding protein 1 (creb1)[J]. Am J Transl Res, 2015,7(10): 2053-2059.
[11]Dayue Liu, Haoming Xia, Fang Wang, et al. Microrna-210 interacts with fbxo31 to regulate cancer proliferation cell cycle and migration in human breast cancer[J]. OncoTargets Ther, 2016, 9: 5245-5255.
[12]Zhang C, Tian W, Meng L, et al. Prl-3 promotes gastric cancer migration and invasion through a nf-kappab-hif-1alpha-mir-210 axis[J]. J Mol Med (Berlin, Germany), 2016, 94(4): 401-415.
[13]Gautam Das, Bhupendra V. Shravage, Eric H. Baehrecke. Regulation and function of autophagy during cell survival and cell death[J]. Cold Spring Harb Perspect Biol, 2012, 4(6): 997-1001.
[14]L Galluzzi, JM Bravo-San Pedro, I Vitale, et al. Essential versus accessory aspects of cell death: recommendations of the nccd 2015[J]. Cell Death Differ, 2015, 22(1): 58-73.
[15]Juliet Goldsmith, Beth Levine, Jayanta Debnath. Autophagy and cancer metabolism[J]. Methods Enzymol, 2014, 542: 25-57.
[16] Banzhou Pan, Bing Feng, Yitian Chen, et al. Mir-200b regulates autophagy associated with chemoresistance in human lung adenocarcinoma[J]. Oncotarget, 2015, 6(32): 32805-32820.
[17]Wang IK, Sun KT, Tsai TH, et al. Mir-20a-5p mediates hypoxia-induced autophagy by targeting atg16l1 in ischemic kidney injury[J]. Life Sciences, 2015, 136: 133-141.
[18]Anne M. Strohecker, Jessie Yanxiang Guo, et al. Autophagy sustains mitochondrial glutamine metabolism and growth of brafv600e-driven lung tumors[J]. Cancer Discov, 2013, 3(11): 1272-1285.
[19]Sergio Comincini, Giulia Allavena, Silvia Palumbo, et al. Microrna-17 regulates the expression of atg7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells[J]. Cancer Biol Ther, 2013, 14(7): 574-586.
[20]Fulda S. Cross talk between cell death regulation and metabolism[J]. Methods Enzymol, 2014, 542: 81-90.
[21]Shenghong Yang, Xiaoxu Wang, Gianmarco Contino, et al. Pancreatic cancers require autophagy for tumor growth[J]. Genes Dev, 2011, 25(7): 717-729. |